| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
CANTON, Mass., (November 5, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solut... |
| 06 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
Organogenesis Holdings Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG”) and Citizens JMP Securities, LLC (“Citizens” and, together with BTIG, the “Agents” and each, an “Agent... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
CANTON, Mass., (August 6, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutio... |
| 16 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
CANTON, Mass., (May 7, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions ... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
CANTON, Mass., (February 26, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products f... |
| 23 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 29 Dec 2025 |
8-K: Entry into a Material Definitive Agreement
THIS FIRST AMENDMENT TO LEASE (this “Amendment”) dated as of December 22, 2025, is entered into between Dan Road Associates, LLC, a Massachusetts limited liability company, with an address at c/o Draxxhall Management Corp., 300 Lighting ... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
CANTON, Mass., (November 6, 2025) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and ... |
| 25 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Change from Baseline WOMAC Pain Scale at 6 Months - Control-based Mean Imputation |
| 07 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
CANTON, Mass., (August 7, 2025) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Su... |
| 24 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
CANTON, Mass., (May 8, 2025) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgi... |
| 27 Mar 2025 |
8-K: Regulation FD Disclosure
FORWARD LOOKING STATEMENTS & OTHER IMPORTANT CAUTIONS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectatio... |
| 27 Feb 2025 |
8-K: Results of Operations and Financial Condition
CANTON, Mass., (February 27, 2025) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products f... |
| 02 Dec 2024 |
8-K: Entry into a Material Definitive Agreement
THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 27, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and GN 2016 Family Trust u/a/d August 12, 2016 (the “Selling ... |
| 22 Nov 2024 |
8-K: Entry into a Material Definitive Agreement; Other Events
Organogenesis Expands Manufacturing Capacity to Support Future Growth |
| 13 Nov 2024 |
8-K: Entry into a Material Definitive Agreement; Triggering Events That Accelerate a Financial Obligation +5 more
This SUBSCRIPTION AGREEMENT (the “Agreement”) is entered into this 12th day of November, 2024, by and among, Organogenesis Holdings Inc., a Delaware corporation (the “Company”), Avista Healthcare Partners III, L.P., a Delaware limited pa... |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition
CANTON, Mass., (November 12, 2024) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and... |
| 08 Aug 2024 |
8-K: Results of Operations and Financial Condition
CANTON, Mass., (August 8, 2024) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Su... |
Loading...